| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
68 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-66 |
| Cash Flow (TTM) (Millions $) |
-56 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Aptinyx Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapies for neurological disorders. The company is engaged in the research and development of advanced therapies with a particular emphasis on the brain's N-methyl-D-aspartate (NMDA) receptor pathway. Aptinyx's drug candidates aim to modulate this pathway to address the underlying causes of various neurological conditions, including chronic pain, cognitive impairment, and movement disorders. The company utilizes its proprietary chemistry platform to develop small molecules that target specific NMDA receptors. Aptinyx's goal is to bring innovative treatments to patients in need, ultimately improving their quality of life.
Company Address: 909 Davis Street Evanston 60201 IL
Company Phone Number: 871-0377 Stock Exchange / Ticker: NASDAQ APTX
|
%
1.75%